Abstract:ID 18908 Poster Board 186 Pregnane X receptor (PXR, NR1I2), a ligand-activated transcription factor, is relatively abundant in liver and intestine. Previous studies have demonstrated that PXR activation inhibits liver fibrosis, but the specific mechanisms still remain unclear. Leukocyte cell-derived chemotaxin 2 (LECT2), a downstream target of β-catenin/ T cell-specific factor 4 (TCF4) signaling, is a small-molecule protein secreted by hepatocytes. Recent study illustrated that LECT2 produced by hepatocytes participated in the progression of hepatic fibrosis by regulating angiogenesis. In the current study, we aimed to investigate whether PXR activation attenuate liver fibrosis by inhibiting LECT2 and explore its impact on β-catenin/TCF4 signaling. Additionally, we also aimed to unveil the critical role of β-catenin/TCF4-LECT2 axis in liver fibrosis and demonstrate whether PXR activation alleviates hepatic fibrosis via inhibiting β-catenin/TCF4-LECT2 axis. In the current study, carbon tetrachloride (CCl4) was used to induce liver fibrosis in C57BL/6 mice. The results showed that mouse PXR agonist pregnenolone-16α-carbonitrile (PCN) significantly attenuated hepatic fibrosis by suppressing the expression of α-smooth muscle actin (α-SMA), Collagen ? and platelet endothelial cell adhesion molecule-1 (CD31). Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) and CD31 staining indicated that PXR activation inhibited sinusoids capillarization and central angiogenesis. Besides, immunohistochemical (IHC) staining and western blot analysis indicated that LECT2 and nuclear β-catenin were significantly downregulated after PXR activation, while total β-catenin and TCF4 didn’t alter significantly. Furthermore, reporter gene assay was performed and suggested that PXR activation inhibited the transcriptional activation of LECT2 by β-catenin/TCF4. PXR activation disrupted the interaction between β-catenin and TCF4. Co-Immunoprecipitation (Co-IP) assays further indicated that PXR potentially interacted with β-catenin and TCF4 simultaneously. Moreover, to clarify whether disrupting β-catenin/TCF4 interaction alleviated liver fibrosis, β-catenin/TCF4 inhibitor LF3 was used to evaluate its effect on liver fibrosis. The results showed the inhibition of β-catenin/TCF4 interaction decreased the expression level of LECT2 and alleviated liver fibrosis. In addition, AAV-Lect2 mice was used and we found that PXR activation failed to protect liver from fibrosis in AAV-Lect2 mice, which further confirmed that PXR attenuated hepatic fibrosis by inhibiting LECT2. Finally, we clarified that long-term treatment of PCN had no risk for carcinogenesis or promoting tumor formation induced by diethylnitrosamine (DEN), indicating the safety of long-term activation of PXR. Taken together, this study demonstrated a new mechanism that PXR attenuated liver fibrosis by disrupting β-catenin/TCF4 interaction and suppressing the expression level of LECT2. The crosstalk between PXR and β-catenin/TCF4 signaling was also clarified. These findings provide new evidence and theoretical basis for PXR as potential drug target for liver fibrosis.

CYP3A suppression during diet-induced nonalcoholic fatty liver disease is independent of PXR regulation

Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet

Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease

Silencing of Functional P53 Attenuates NAFLD by Promoting HMGB1-related Autophagy Induction

The Roles and Interaction of FXR and PPARs in the Pathogenesis of Nonalcoholic Fatty Liver Disease

N-3 Polyunsaturated Fatty Acids in Phospholipid or Triacylglycerol Form Attenuate Nonalcoholic Fatty Liver Disease Via Mediating Cannabinoid Receptor 1/adiponectin/ceramide Pathway.

Impaired adipose expansion caused by liver X receptor activation is associated with insulin resistance in mice fed a high-fat diet.

Clofibrate and perfluorodecanoate both upregulate the expression of the pregnane X receptor but oppositely affect its ligand-dependent induction on cytochrome P450 3A23.

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Metabolomics reveals dysregulated all-trans retinoic acid and polyunsaturated fatty acid metabolism contribute to PXR-induced hepatic steatosis in mice

Effects of Fatty Acids on CYP2A5 and Nrf2 Expression in Mouse Primary Hepatocytes

A Novel Pregnane X Receptor-Mediated and Sterol Regulatory Element-Binding Protein-Independent Lipogenic Pathway

PXR Functionally Interacts with NF-κB and AP-1 to Downregulate the Inflammation-Induced Expression of Chemokine CXCL2 in Mice

PXR Activation Attenuates Liver Fibrosis by Down-Regulating LECT2 and Disrupting -Catenin/tcf4 Interaction

PXR Suppresses PPARα-Dependent HMGCS2 Gene Transcription by Inhibiting the Interaction between PPARα and PGC1α

Farnesoid X receptor down-regulates expression of liver fatty acid-binding protein in liver cells

PXR and LXR in hepatic steatosis: a new dog and an old dog with new tricks.

Hepatocyte-specific Nrf2 Deficiency Mitigates High-Fat Diet-Induced Hepatic Steatosis: Involvement of Reduced PPARγ Expression

Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease

Kupffer cells suppress perfluorononanoic acid-induced hepatic peroxisome proliferator-activated receptor α expression by releasing cytokines